Structure Activity Relationships of 5-, 6-, and 7-Methyl-Substituted Azepan-3-one Cathepsin K Inhibitors

The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substit...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 49; no. 5; pp. 1597 - 1612
Main Authors Yamashita, Dennis S, Marquis, Robert W, Xie, Ren, Nidamarthy, Sirishkumar D, Oh, Hye-Ja, Jeong, Jae U, Erhard, Karl F, Ward, Keith W, Roethke, Theresa J, Smith, Brian R, Cheng, H-Y, Geng, Xiaoliu, Lin, Fan, Offen, Priscilla H, Wang, Bing, Nevins, Neysa, Head, Martha S, Haltiwanger, R. Curtis, Narducci Sarjeant, Amy A, Liable-Sands, Louise M, Zhao, Baoguang, Smith, Ward W, Janson, Cheryl A, Gao, Enoch, Tomaszek, Thaddeus, McQueney, Michael, James, Ian E, Gress, Catherine J, Zembryki, Denise L, Lark, Michael W, Veber, Daniel F
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 09.03.2006
Amer Chemical Soc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K i,app = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K i,app = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere.
AbstractList The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K i,app = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K i,app = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere.
The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K(i,app) = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K(i,app) = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere.The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K(i,app) = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K(i,app) = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere.
The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-iiiethyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K-i,K-app = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K-i,K-app = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere.
Author Offen, Priscilla H
Lark, Michael W
Wang, Bing
Veber, Daniel F
Marquis, Robert W
Nidamarthy, Sirishkumar D
Roethke, Theresa J
James, Ian E
Cheng, H-Y
Tomaszek, Thaddeus
Lin, Fan
Smith, Ward W
Ward, Keith W
Zhao, Baoguang
Head, Martha S
Yamashita, Dennis S
Smith, Brian R
Erhard, Karl F
McQueney, Michael
Liable-Sands, Louise M
Gress, Catherine J
Janson, Cheryl A
Geng, Xiaoliu
Nevins, Neysa
Narducci Sarjeant, Amy A
Xie, Ren
Jeong, Jae U
Haltiwanger, R. Curtis
Oh, Hye-Ja
Gao, Enoch
Zembryki, Denise L
Author_xml – sequence: 1
  givenname: Dennis S
  surname: Yamashita
  fullname: Yamashita, Dennis S
– sequence: 2
  givenname: Robert W
  surname: Marquis
  fullname: Marquis, Robert W
– sequence: 3
  givenname: Ren
  surname: Xie
  fullname: Xie, Ren
– sequence: 4
  givenname: Sirishkumar D
  surname: Nidamarthy
  fullname: Nidamarthy, Sirishkumar D
– sequence: 5
  givenname: Hye-Ja
  surname: Oh
  fullname: Oh, Hye-Ja
– sequence: 6
  givenname: Jae U
  surname: Jeong
  fullname: Jeong, Jae U
– sequence: 7
  givenname: Karl F
  surname: Erhard
  fullname: Erhard, Karl F
– sequence: 8
  givenname: Keith W
  surname: Ward
  fullname: Ward, Keith W
– sequence: 9
  givenname: Theresa J
  surname: Roethke
  fullname: Roethke, Theresa J
– sequence: 10
  givenname: Brian R
  surname: Smith
  fullname: Smith, Brian R
– sequence: 11
  givenname: H-Y
  surname: Cheng
  fullname: Cheng, H-Y
– sequence: 12
  givenname: Xiaoliu
  surname: Geng
  fullname: Geng, Xiaoliu
– sequence: 13
  givenname: Fan
  surname: Lin
  fullname: Lin, Fan
– sequence: 14
  givenname: Priscilla H
  surname: Offen
  fullname: Offen, Priscilla H
– sequence: 15
  givenname: Bing
  surname: Wang
  fullname: Wang, Bing
– sequence: 16
  givenname: Neysa
  surname: Nevins
  fullname: Nevins, Neysa
– sequence: 17
  givenname: Martha S
  surname: Head
  fullname: Head, Martha S
– sequence: 18
  givenname: R. Curtis
  surname: Haltiwanger
  fullname: Haltiwanger, R. Curtis
– sequence: 19
  givenname: Amy A
  surname: Narducci Sarjeant
  fullname: Narducci Sarjeant, Amy A
– sequence: 20
  givenname: Louise M
  surname: Liable-Sands
  fullname: Liable-Sands, Louise M
– sequence: 21
  givenname: Baoguang
  surname: Zhao
  fullname: Zhao, Baoguang
– sequence: 22
  givenname: Ward W
  surname: Smith
  fullname: Smith, Ward W
– sequence: 23
  givenname: Cheryl A
  surname: Janson
  fullname: Janson, Cheryl A
– sequence: 24
  givenname: Enoch
  surname: Gao
  fullname: Gao, Enoch
– sequence: 25
  givenname: Thaddeus
  surname: Tomaszek
  fullname: Tomaszek, Thaddeus
– sequence: 26
  givenname: Michael
  surname: McQueney
  fullname: McQueney, Michael
– sequence: 27
  givenname: Ian E
  surname: James
  fullname: James, Ian E
– sequence: 28
  givenname: Catherine J
  surname: Gress
  fullname: Gress, Catherine J
– sequence: 29
  givenname: Denise L
  surname: Zembryki
  fullname: Zembryki, Denise L
– sequence: 30
  givenname: Michael W
  surname: Lark
  fullname: Lark, Michael W
– sequence: 31
  givenname: Daniel F
  surname: Veber
  fullname: Veber, Daniel F
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17595047$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16509577$$D View this record in MEDLINE/PubMed
BookMark eNqNkkGP0zAQhS20iO0uHPgDKBdWQmDWdmI7OVYFll2KQLSIo-U4E9UldYLtAOXX49LSldAeOFgeyd8bP72ZM3TiegcIPabkJSWMXq43hJOK8vEemlDOCC5KUpygCSGMYSZYforOQlgTQnLK8gfolIrEcyknaLWIfjRx9JBNTbTfbdxmn6DT0fYurOwQsr7NOH6RiXS0azKJ30NcbTu8GOsQbRwjNNn0Fwza4RwnX9lMxxUMwbrsXXbtVra2sffhIbrf6i7Ao8N9jj6_eb2cvcXzD1fXs-kc66KQETeFJAJaQUTF6rIptDC8bBmQoiWQqkqIipO6rKkRHPKiaspaVCVrtM6ByTI_Rxf7voPvv40QotrYYKDrtIN-DEpISakkLIFPDuBYb6BRg7cb7bfqbzYJeHoAdDC6a712xoZbTvLkpNhxz_fcD6j7NhgLzsARS6GzXBDCi1TR3bfl_9MzG_9MYtaPLibp5V5qfB-Ch1aZw3v02naKErVbB3Vch6R49o_i6P4OFu9ZGyL8PILaf02Z5ZKr5ceFqr7cLK9u5qV6dRuPNkGt-9G7NNY7-v4GuffLhw
CODEN JMCMAR
CitedBy_id crossref_primary_10_1016_j_bmcl_2008_12_053
crossref_primary_10_3390_molecules22111871
crossref_primary_10_1021_bi8007627
crossref_primary_10_1096_fj_06_7924com
crossref_primary_10_1007_s00223_009_9279_x
crossref_primary_10_1002_asia_201000817
crossref_primary_10_3390_molecules30010091
crossref_primary_10_3390_curroncol29080471
crossref_primary_10_1021_acssuschemeng_1c06522
crossref_primary_10_1021_op700288p
crossref_primary_10_1080_14756366_2018_1465417
crossref_primary_10_1016_j_bmc_2006_08_040
crossref_primary_10_1021_jm3007257
crossref_primary_10_1517_13543776_2011_616283
crossref_primary_10_1016_j_bone_2015_07_016
crossref_primary_10_1517_13543780902832661
crossref_primary_10_1016_j_cbpa_2014_08_011
crossref_primary_10_1016_j_bone_2006_07_015
crossref_primary_10_1039_c2ra21302h
crossref_primary_10_1021_acsomega_8b03258
crossref_primary_10_1007_s12018_011_9094_6
crossref_primary_10_1016_j_tet_2009_06_022
crossref_primary_10_3389_fimmu_2015_00252
crossref_primary_10_1038_nrrheum_2011_77
crossref_primary_10_1021_op100266s
crossref_primary_10_1039_D1QO00070E
crossref_primary_10_1021_jm9018756
crossref_primary_10_1517_13543771003604729
crossref_primary_10_1016_j_tetlet_2014_02_116
crossref_primary_10_1186_s12891_017_1625_y
crossref_primary_10_1016_j_bmcl_2007_12_047
crossref_primary_10_3390_jcm2040176
crossref_primary_10_1016_j_pharmthera_2011_04_010
crossref_primary_10_1039_C7CC03307A
crossref_primary_10_1074_jbc_M110_126706
crossref_primary_10_1016_j_bmcl_2011_06_045
crossref_primary_10_1016_j_chembiol_2007_03_010
crossref_primary_10_1039_C6RA14251F
crossref_primary_10_1177_1759720X13490860
crossref_primary_10_1359_jbmr_091035
crossref_primary_10_1007_s11914_011_0085_9
crossref_primary_10_1016_j_isci_2022_104131
crossref_primary_10_1039_C8RA10338K
crossref_primary_10_3762_bjoc_7_106
crossref_primary_10_1134_S1070428011030195
crossref_primary_10_3390_catal12101087
Cites_doi 10.1021/jm020017n
10.2165/00003088-199223060-00005
10.1359/jbmr.1999.14.9.1562
10.1021/ac00238a024
10.1021/jo9824450
10.1359/jbmr.2001.16.10.1739
10.1021/bi00014a037
10.1002/jcc.540110405
10.1021/ja972204u
10.1016/S0040-4020(00)00965-0
10.1038/nsb0297-109
10.1021/ja01002a037
10.1016/S0169-409X(00)00129-0
10.1021/jm000942e
10.1021/ja00221a048
10.1016/S0065-7743(04)39007-X
10.1021/jm000481x
10.1016/j.tet.2004.05.124
ContentType Journal Article
Copyright Copyright © 2006 American Chemical Society
2006 INIST-CNRS
Copyright_xml – notice: Copyright © 2006 American Chemical Society
– notice: 2006 INIST-CNRS
DBID BSCLL
AAYXX
CITATION
17B
1KM
BLEPL
DTL
EGQ
GAHYA
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1021/jm050915u
DatabaseName Istex
CrossRef
Web of Knowledge
Index Chemicus
Web of Science Core Collection
Science Citation Index Expanded
Web of Science Primary (SCIE, SSCI & AHCI)
Web of Science - Science Citation Index Expanded - 2006
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
Web of Science
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Web of Science
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 1KM
  name: Index Chemicus
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC
  sourceTypes:
    Enrichment Source
    Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-4804
EndPage 1612
ExternalDocumentID 16509577
17595047
000236005400012
10_1021_jm050915u
ark_67375_TPS_9WJTGJL8_D
b65801388
Genre Journal Article
GroupedDBID -
.K2
4.4
53G
55A
5GY
5RE
5VS
7~N
AABXI
ABFLS
ABMVS
ABOCM
ABPTK
ABUCX
ACGFS
ACJ
ACS
AEESW
AENEX
AFEFF
AFFNX
ALMA_UNASSIGNED_HOLDINGS
ANTXH
AQSVZ
BAANH
CS3
DU5
EBS
ED
ED~
EJD
F5P
GJ
GNL
IH9
IHE
JG
JG~
K2
L7B
LG6
NHB
P2P
ROL
TN5
UI2
VF5
VG9
W1F
WH7
X
XFK
YZZ
ZY4
---
-~X
.GJ
AAHBH
AAYOK
ABJNI
ABQRX
ABTAH
ACGFO
ADHLV
AGXLV
AHGAQ
BSCLL
CUPRZ
GGK
IH2
XSW
YQT
AAYXX
ABBLG
ABLBI
ACRPL
ADNMO
AEYZD
AGQPQ
ANPPW
CITATION
17B
1KM
BLEPL
DTL
GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED
GROUPED_WOS_WEB_OF_SCIENCE
.55
.HR
1KJ
1WB
3EH
3O-
6P2
6TJ
9M8
ABHMW
ADXHL
IQODW
MVM
OHT
RNS
UBC
X7M
ZE2
ZGI
CGR
CUY
CVF
ECM
EIF
NPM
VXZ
YIN
7X8
ID FETCH-LOGICAL-a447t-d4706ef60692b8d4a6c58f2e04f0e58f966950b8b1c65e349d8b6982daa3e2783
IEDL.DBID ACS
ISICitedReferencesCount 59
ISICitedReferencesURI https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000236005400012
ISSN 0022-2623
IngestDate Mon Jul 21 10:03:11 EDT 2025
Wed Feb 19 01:42:19 EST 2025
Mon Jul 21 09:13:57 EDT 2025
Fri Aug 29 16:14:40 EDT 2025
Wed Aug 06 05:58:34 EDT 2025
Thu Apr 24 23:07:34 EDT 2025
Tue Jul 01 02:12:54 EDT 2025
Wed Oct 30 09:58:52 EDT 2024
Thu Aug 27 13:42:07 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords DESIGN
POTENT
ASSAY
CRYSTAL-STRUCTURE
BINDING
CONFORMATIONS
MOLECULES
Intravenous administration
Rat
Cysteine endopeptidases
Monkey
Non peptide compound
Clearance
Pyridine derivatives
Structure activity relation
Primates
Chemical synthesis
Cathepsin K
Sulfonamide
Enzyme
Rodentia
Oral administration
Enzyme inhibitor
Resorption
Bioavailability
In vitro
Peptidases
Vertebrata
Mammalia
Animal
Hydrolases
Carboxamide
Benzofuran derivatives
Bone
Pharmacokinetics
Language English
License CC BY 4.0
LinkModel DirectLink
LogoURL https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg
MergedId FETCHMERGED-LOGICAL-a447t-d4706ef60692b8d4a6c58f2e04f0e58f966950b8b1c65e349d8b6982daa3e2783
Notes istex:FC16672AD431F4665E82A71D84D51E5530A0082A
ark:/67375/TPS-9WJTGJL8-D
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-2378-7283
PMID 16509577
PQID 67711702
PQPubID 23479
PageCount 16
ParticipantIDs proquest_miscellaneous_67711702
webofscience_primary_000236005400012
pubmed_primary_16509577
acs_journals_10_1021_jm050915u
pascalfrancis_primary_17595047
istex_primary_ark_67375_TPS_9WJTGJL8_D
crossref_primary_10_1021_jm050915u
crossref_citationtrail_10_1021_jm050915u
webofscience_primary_000236005400012CitationCount
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
ACJ
VG9
W1F
ANTXH
ACS
AEESW
AFEFF
.K2
ABMVS
ABUCX
IH9
BAANH
AQSVZ
ED~
UI2
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2006-03-09
PublicationDateYYYYMMDD 2006-03-09
PublicationDate_xml – month: 03
  year: 2006
  text: 2006-03-09
  day: 09
PublicationDecade 2000
PublicationPlace WASHINGTON
PublicationPlace_xml – name: WASHINGTON
– name: Washington, DC
– name: United States
PublicationTitle Journal of medicinal chemistry
PublicationTitleAbbrev J MED CHEM
PublicationTitleAlternate J. Med. Chem
PublicationYear 2006
Publisher American Chemical Society
Amer Chemical Soc
Publisher_xml – name: American Chemical Society
– name: Amer Chemical Soc
References Thompson M. (jm050915ub00011/jm050915ub00011_1) 1982; 54
Yamashita D. S. (jm050915ub00002/jm050915ub00002_1) 1997; 119
Stroup G. B. (jm050915ub00001/jm050915ub00001_1) 2001; 16
Veber D. F. (jm050915ub00013/jm050915ub00013_1) 2002; 45
Ertl P. (jm050915ub00015/jm050915ub00015_1) 2000; 43
James I. E. (jm050915ub00010/jm050915ub00010_1) 1999; 14
Morrison J. F. (jm050915ub00017/jm050915ub00017_1) 1988; 61
Gabrielsson J. (jm050915ub00019/jm050915ub00019_1) 1997
Gula M. J. (jm050915ub00007/jm050915ub00007_1) 1988; 110
Brandt M. (jm050915ub00016/jm050915ub00016_1) 1989; 28
Marquis R. W. (jm050915ub00003/jm050915ub00003_1) 2001; 44
Pacifici G. M. (jm050915ub00020/jm050915ub00020_1) 1992; 23
Luzzio F. A (jm050915ub00004/jm050915ub00004_1) 2001; 57
Grubbs R. H. (jm050915ub00005/jm050915ub00005_1) 2004; 60
Hendrickson J. B. (jm050915ub00006/jm050915ub00006_1) 1967; 89
Lipinski C. A. (jm050915ub00014/jm050915ub00014_1) 2001; 46
Zhao B. (jm050915ub00009/jm050915ub00009_1) 1997; 4
Turk D. (jm050915ub00012/jm050915ub00012_1) 1995; 34
Mohamadi F. (jm050915ub00018/jm050915ub00018_1) 1990; 11
Nevins N. (jm050915ub00008/jm050915ub00008_1) 1999; 64
Stroup, GB (WOS:000171142000001) 2001; 16
TURK, D (WOS:A1995QT03200037) 1995; 34
PACIFICI, GM (WOS:A1992KA09300004) 1992; 23
James, IE (WOS:000082276000012) 1999; 14
Grubbs, RH (WOS:000223090800003) 2004; 60
Luzzio, FA (WOS:000166786700001) 2001; 57
FAVINI G (WOS:000236005400012.3) 1983; 93
Kansy, M (WOS:000072852600001) 1998; 41
Yamashita, DS (WOS:000085302300002) 2000; 6
MOHAMADI, F (WOS:A1990CZ22100004) 1990; 11
Veber, DF (WOS:000175957700030) 2002; 45
THOMPSON, M (WOS:A1982MW08100026) 1982; 54
Marquis, RW (WOS:000168443100009) 2001; 44
BRANDT, M (WOS:A1989R737300021) 1989; 28
HENDRICKSON, JB (WOS:A1967A393800036) 1967; 89
Marquis, RW (WOS:000228477500007) 2004; 39
GABRIELSSON J (WOS:000236005400012.4) 1997
Zhao, BG (WOS:A1997WF96100009) 1997; 4
Marquis, RW (WOS:000075892000003) 1998; 41
Snyder, JP (WOS:000085165200028) 2000; 122
MORRISON, JF (WOS:A1988N206500005) 1988; 61
GULA, MJ (WOS:A1988P073900047) 1988; 110
Nevins, N (WOS:000080681400035) 1999; 64
Ertl, P (WOS:000089725000014) 2000; 43
Lipinski, CA (WOS:000167611100002) 2001; 46
Yamashita, DS (WOS:A1997YG90100039) 1997; 119
References_xml – volume: 45
  start-page: 2623
  year: 2002
  ident: jm050915ub00013/jm050915ub00013_1
  publication-title: J. Med. Chem.
  doi: 10.1021/jm020017n
– volume: 23
  start-page: 468
  year: 1992
  ident: jm050915ub00020/jm050915ub00020_1
  publication-title: Clin. Pharmacokinet.
  doi: 10.2165/00003088-199223060-00005
– volume: 14
  start-page: 1569
  year: 1999
  ident: jm050915ub00010/jm050915ub00010_1
  publication-title: J. Bone Miner. Res.
  doi: 10.1359/jbmr.1999.14.9.1562
– volume: 54
  start-page: 81
  year: 1982
  ident: jm050915ub00011/jm050915ub00011_1
  publication-title: Anal. Chem.
  doi: 10.1021/ac00238a024
– volume: 61
  start-page: 301
  year: 1988
  ident: jm050915ub00017/jm050915ub00017_1
  publication-title: Adv. Enzymol. Relat. Areas Mol. Biol.
– volume: 64
  start-page: 3986
  issue: 11
  year: 1999
  ident: jm050915ub00008/jm050915ub00008_1
  publication-title: J. Org. Chem.
  doi: 10.1021/jo9824450
– volume: 16
  start-page: 1746
  issue: 10
  year: 2001
  ident: jm050915ub00001/jm050915ub00001_1
  publication-title: J. Bone Miner. Res.
  doi: 10.1359/jbmr.2001.16.10.1739
– volume: 34
  start-page: 4797
  year: 1995
  ident: jm050915ub00012/jm050915ub00012_1
  publication-title: Biochemistry
  doi: 10.1021/bi00014a037
– volume: 11
  start-page: 467
  issue: 4
  year: 1990
  ident: jm050915ub00018/jm050915ub00018_1
  publication-title: J. Comput. Chem.
  doi: 10.1002/jcc.540110405
– volume: 119
  start-page: 11352
  year: 1997
  ident: jm050915ub00002/jm050915ub00002_1
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/ja972204u
– volume: 57
  start-page: 945
  year: 2001
  ident: jm050915ub00004/jm050915ub00004_1
  publication-title: Tetrahedron
  doi: 10.1016/S0040-4020(00)00965-0
– volume: 4
  start-page: 111
  issue: 2
  year: 1997
  ident: jm050915ub00009/jm050915ub00009_1
  publication-title: Nat. Struct. Biol.
  doi: 10.1038/nsb0297-109
– volume: 28
  start-page: 148
  year: 1989
  ident: jm050915ub00016/jm050915ub00016_1
  publication-title: Biochemistry
– volume-title: Pharmacokinetic and Pharmacodynamic Data Analysis:  Concepts and Applications
  year: 1997
  ident: jm050915ub00019/jm050915ub00019_1
– volume: 60
  start-page: 7140
  year: 2004
  ident: jm050915ub00005/jm050915ub00005_1
  publication-title: Tetrahedron
– volume: 89
  start-page: 7043
  year: 1967
  ident: jm050915ub00006/jm050915ub00006_1
  publication-title: Am. Chem. Soc.
  doi: 10.1021/ja01002a037
– volume: 46
  start-page: 26
  year: 2001
  ident: jm050915ub00014/jm050915ub00014_1
  publication-title: Adv. Drug. Del. Rev.
  doi: 10.1016/S0169-409X(00)00129-0
– volume: 43
  start-page: 3717
  year: 2000
  ident: jm050915ub00015/jm050915ub00015_1
  publication-title: J. Med. Chem.
  doi: 10.1021/jm000942e
– volume: 44
  start-page: 1395
  year: 2001
  ident: jm050915ub00003/jm050915ub00003_1
  publication-title: J. Med. Chem.
– volume: 110
  start-page: 4405
  year: 1988
  ident: jm050915ub00007/jm050915ub00007_1
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/ja00221a048
– volume: 119
  start-page: 11351
  year: 1997
  ident: WOS:A1997YG90100039
  article-title: Structure and design of potent and selective cathepsin K inhibitors
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
– volume: 43
  start-page: 3714
  year: 2000
  ident: WOS:000089725000014
  article-title: Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
– volume: 93
  start-page: 139
  year: 1983
  ident: WOS:000236005400012.3
  publication-title: J MOL STRUCT
– volume: 41
  start-page: 3563
  year: 1998
  ident: WOS:000075892000003
  article-title: Conformationally constrained 1,3-diamino ketones: A series of potent inhibitors of the cysteine protease cathepsin K
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
– volume: 11
  start-page: 440
  year: 1990
  ident: WOS:A1990CZ22100004
  article-title: MACROMODEL - AN INTEGRATED SOFTWARE SYSTEM FOR MODELING ORGANIC AND BIOORGANIC MOLECULES USING MOLECULAR MECHANICS
  publication-title: JOURNAL OF COMPUTATIONAL CHEMISTRY
– volume: 45
  start-page: 2615
  year: 2002
  ident: WOS:000175957700030
  article-title: Molecular properties that influence the oral bioavailability of drug candidates
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm020017n
– volume: 23
  start-page: 449
  year: 1992
  ident: WOS:A1992KA09300004
  article-title: METHODS OF DETERMINING PLASMA AND TISSUE BINDING OF DRUGS - PHARMACOKINETIC CONSEQUENCES
  publication-title: CLINICAL PHARMACOKINETICS
– volume: 61
  start-page: 201
  year: 1988
  ident: WOS:A1988N206500005
  article-title: THE BEHAVIOR AND SIGNIFICANCE OF SLOW-BINDING ENZYME-INHIBITORS
  publication-title: ADVANCES IN ENZYMOLOGY AND RELATED AREAS OF MOLECULAR BIOLOGY
– volume: 28
  start-page: 140
  year: 1989
  ident: WOS:A1989R737300021
  article-title: 3-BETA-HYDROXY-DELTA-5-STEROID DEHYDROGENASE/3-KETO-DELTA-5-STEROID ISOMERASE FROM BOVINE ADRENALS - MECHANISM OF INHIBITION BY 3-OXO-4-AZA STEROIDS AND KINETIC MECHANISM OF THE DEHYDROGENASE
  publication-title: BIOCHEMISTRY
– year: 1997
  ident: WOS:000236005400012.4
  publication-title: PHARMACOKINETIC PHAR
– volume: 14
  start-page: 1562
  year: 1999
  ident: WOS:000082276000012
  article-title: Development and characterization of a human in vitro resorption assay: Demonstration of utility using novel antiresorptive agents
  publication-title: JOURNAL OF BONE AND MINERAL RESEARCH
– volume: 34
  start-page: 4791
  year: 1995
  ident: WOS:A1995QT03200037
  article-title: CRYSTAL-STRUCTURE OF CATHEPSIN-B INHIBITED WITH CA030 AT 2.0-ANGSTROM RESOLUTION - A BASIS FOR THE DESIGN OF SPECIFIC EPOXYSUCCINYL INHIBITORS
  publication-title: BIOCHEMISTRY
– volume: 54
  start-page: 76
  year: 1982
  ident: WOS:A1982MW08100026
  article-title: STRUCTURE AND ELECTROCHEMICAL PROPERTIES OF MICRO-FILTRATION FILTER LIPID-MEMBRANE SYSTEMS
  publication-title: ANALYTICAL CHEMISTRY
– volume: 6
  start-page: 1
  year: 2000
  ident: WOS:000085302300002
  article-title: Cathepsin K and the design of inhibitors of cathepsin K
  publication-title: CURRENT PHARMACEUTICAL DESIGN
– volume: 41
  start-page: 1007
  year: 1998
  ident: WOS:000072852600001
  article-title: Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
– volume: 39
  start-page: 79
  year: 2004
  ident: WOS:000228477500007
  article-title: Inhibition of the cysteine protease cathepsin K (EC 3.4.22.38)
  publication-title: ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 39
  doi: 10.1016/S0065-7743(04)39007-X
– volume: 44
  start-page: 1380
  year: 2001
  ident: WOS:000168443100009
  article-title: Azepanone-based inhibitors of human and rat cathepsin K
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm000481x
– volume: 16
  start-page: 1739
  year: 2001
  ident: WOS:000171142000001
  article-title: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate
  publication-title: JOURNAL OF BONE AND MINERAL RESEARCH
– volume: 64
  start-page: 3979
  year: 1999
  ident: WOS:000080681400035
  article-title: A test of the single-conformation hypothesis in the analysis of NMR data for small polar molecules: A force field comparison
  publication-title: JOURNAL OF ORGANIC CHEMISTRY
– volume: 57
  start-page: 915
  year: 2001
  ident: WOS:000166786700001
  article-title: The Henry reaction: recent examples
  publication-title: TETRAHEDRON
– volume: 4
  start-page: 109
  year: 1997
  ident: WOS:A1997WF96100009
  article-title: Crystal structure of human osteoclast cathepsin K complex with E-64
  publication-title: NATURE STRUCTURAL BIOLOGY
– volume: 46
  start-page: 3
  year: 2001
  ident: WOS:000167611100002
  article-title: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings (Reprinted from Advanced Drug Delivery Reviews, vol 23, pg 3-25, 1997)
  publication-title: ADVANCED DRUG DELIVERY REVIEWS
– volume: 122
  start-page: 724
  year: 2000
  ident: WOS:000085165200028
  article-title: The conformations of taxol in chloroform
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
– volume: 89
  start-page: 7036
  year: 1967
  ident: WOS:A1967A393800036
  article-title: MOLECULAR GEOMETRY .V. EVALUATION OF FUNCTIONS AND CONFORMATIONS OF MEDIUM RINGS
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
– volume: 110
  start-page: 4400
  year: 1988
  ident: WOS:A1988P073900047
  article-title: EVALUATION OF 1,3-DIAXIAL STERIC HINDRANCE TO PROTON ABSTRACTION ALPHA TO CARBONYL GROUPS
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
– volume: 60
  start-page: 7117
  year: 2004
  ident: WOS:000223090800003
  article-title: Olefin metathesis
  publication-title: TETRAHEDRON
  doi: 10.1016/j.tet.2004.05.124
SSID ssj0003123
Score 2.105938
Snippet The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based...
The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-iiiethyl-substituted...
Source Web of Science
SourceID proquest
pubmed
pascalfrancis
webofscience
crossref
istex
acs
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1597
SubjectTerms Animals
Azepines - chemical synthesis
Azepines - chemistry
Azepines - pharmacology
Biological and medical sciences
Biological Availability
Blood Proteins - metabolism
Bone Density Conservation Agents - chemical synthesis
Bone Density Conservation Agents - chemistry
Bone Density Conservation Agents - pharmacology
Bones, joints and connective tissue. Antiinflammatory agents
Cathepsin K
Cathepsins - antagonists & inhibitors
Cathepsins - chemistry
Cell Line
Cell Membrane Permeability
Chemistry, Medicinal
Crystallography, X-Ray
Haplorhini
Humans
Life Sciences & Biomedicine
Medical sciences
Molecular Conformation
Pharmacology & Pharmacy
Pharmacology. Drug treatments
Protein Binding
Rats
Science & Technology
Stereoisomerism
Structure-Activity Relationship
Sulfones - chemical synthesis
Sulfones - chemistry
Sulfones - pharmacology
Title Structure Activity Relationships of 5-, 6-, and 7-Methyl-Substituted Azepan-3-one Cathepsin K Inhibitors
URI http://dx.doi.org/10.1021/jm050915u
https://api.istex.fr/ark:/67375/TPS-9WJTGJL8-D/fulltext.pdf
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000236005400012
https://www.ncbi.nlm.nih.gov/pubmed/16509577
https://www.proquest.com/docview/67711702
Volume 49
WOS 000236005400012
WOSCitedRecordID wos000236005400012
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfG9gAvAwaM8DEsmCoe6pE4tmM_Vh1jFIYqtRN7i-zEUbuNtFpaie2v55yvbqJ8PESKlLMT3519d_H5dwjtSyWo8WVKGMsgQBG-JcpQTSCYEJzLLKEldufJN3F8ygZn_GwDvfvDDj4NPpz_cBAlAV_eQ1tUyMhFWL3-qF1uw4CGDSQ4BWPewAfdbupMT1LcMT1bjos_XSqkLoAbWVXGYp2fudYklebn6CE6bA7xVFknFwfLhTlIbn7HdPzbyB6h7dr9xL1KXx6jDZvvoPv9purbDuoMKyzr6y4er45mFV3cwcMVyvX1EzQZlcizyyuLe0lVggK3mXWT6bzAswxz0sUCLp2nOCInFrTikri1qkpQSHHvBsxhTkIyyy0uTyPOi2mOv-DP-WRqpq4U0FN0evRx3D8mddkGohmLFiRlkS9sBpGRokamTIsEhE6tzzLfwh0EWIr7RpogEdyGTKXSCCVpqnVoXeGPZ2gzh7c-R1hLppIsVJpnmlnFjAHvzgZCS8FsIgMP7YFc43raFXG5o04homk466H3jcjjpAY9d7U3LteRvm1J5xXSxzqiTqk3LYW-unCpcRGPx8NRrL4Pxp8GX2V8CF92R7FWXUYcRs8iD71pNC0GEbttGp3b2bKA7iJXDoh6aLdSwFVbB3fII2i7f1sj2-clepEovXDnxnoo-B-yfs0XB4KwePEvjr5ED6q_UCHx1Su0CbpmX4NftjB75bz8BXUWLcU
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9swELc2eGAv-2BfZRtYE6r2UEPi2E78WHVjpbSoUovGW2QnjtoBaUVaafDX7-wkLUyVxkOkSDk79uWX3F18_h1Ch5EUVHtRShjLIEARniFSU0UgmBCcR1lCHXfn4Fx0L1jvkl9WNDl2LwwMooCeCreIv2YX8I9_31imEp8vn6NtcEKoDbTandHqqxv4NKiZwSnY9JpF6GFTa4GS4pEF2rbK_GMzIlUBSsnKahab3M2NlslZoZNXZTkjN36XfHJ1tFzoo-T-H2rHp03wNXpZOaO4XaLnDXpm8l2006lrwO2i5rBktr5r4fF6o1bRwk08XHNe371Fk5HjoV3eGtxOyoIUeJVnN5nOCzzLMCctLOBQeYpDMjCAkWtiv1xlukKK2_dgHHMSkFlusNubOC-mOT7Dp_lkqqe2MNA7dHHyY9zpkqqIA1GMhQuSstATJoM4SVIdpUyJBCBAjccyz8AZhFuSezrSfiK4CZhMIy1kRFOlAmPLgLxHWznc9SPCKmIyyQKpeKaYkUxr8PWML1QkmEkiv4H2QbFx9RIWsVtfpxDf1JptoG_1k4-TigLdVuK43iT6dSU6L3k_Ngk1HXxWEur2yibKhTweD0ex_NUb_-z1o_g7jOwRvtZdhhxmz8IGOqgBF8Mjtos2KjezZQHdhbY4EG2gDyUO120t-SEPoe3hQ2CurjsuI-F8cuvUNpD_FLFOpRdLibDY-59GD9BOdzzox_3T87NP6EX5fyognvyMtgB35gt4bAu9717Vv7wgNiY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9swELc2kLa9jI2NLfsAa0LVHmqWD8exH6tCB-VjlVo03iI7cdQOllaklQZ_PWfno4AqjYdIkXJx7MvPubv4_DuEdrlgvnJ5SijNIEBhriZC-ZJAMMHCkGeJb7k7T8_Y4TntX4QXVaBo9sJAJwpoqbCL-GZWz9KsYhjwfvz5a9hKvHDxHK2b5ToTbHW6w-bLG3h-ULOD-2DXayah-7caK5QUD6zQulHoP5MVKQtQTFZWtFjlcq60TtYS9TbQr2YMNgHlcm8xV3vJ7SN6x6cP8g16XTmluFOi6C16pvNN9LJb14LbRK1ByXB908aj5Yatoo1beLDkvr55h8ZDy0e7uNa4k5SFKXCTbzeezAo8zXBI2pjBIfMUR-RUA1auiPmClWkLKe7cgpHMSUCmucZ2j-KsmOT4GB_l44mamAJB79F572DUPSRVMQciKY3mJKWRy3QG8ZLwFU-pZAlAwdcuzVwNZxB2idBVXHkJC3VARcoVE9xPpQy0KQeyhdZyeOpHhCWnIskCIcNMUi2oUuDzaY9JzqhOuOegbVBuXE3GIrbr7D7EObVmHfS9fvtxUlGhm4ocV6tEvzWis5L_Y5VQy0KokZDXlyZhLgrj0WAYi9_90c_-CY_3oWcPMLZsMgph9DRy0E4NuhhesVm8kbmeLgpoLjJFgnwHfSixuLzXkCDCZHDQ7n1wNtctpxGzvrlxbh3kPUWsW-nFUCPMP_1PozvoxWC_F58cnR1_Rq_K31QBccUXtAaw01_BcZurbTtb7wDGTDip
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structure+Activity+Relationships+of+5-%2C+6-%2C+and+7-Methyl-Substituted+Azepan-3-one+Cathepsin+K+Inhibitors&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Yamashita%2C+Dennis+S&rft.au=Marquis%2C+Robert+W&rft.au=Xie%2C+Ren&rft.au=Nidamarthy%2C+Sirishkumar+D&rft.date=2006-03-09&rft.pub=American+Chemical+Society&rft.issn=0022-2623&rft.eissn=1520-4804&rft.volume=49&rft.issue=5&rft.spage=1597&rft.epage=1612&rft_id=info:doi/10.1021%2Fjm050915u&rft.externalDocID=b65801388
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon